# Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-ii-study-of-erlotinib-in-recurrent-or-metastatic-endometrial-cancer-ncic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Amit M. Oza,Elizabeth A. Eisenhauer,Laurie Elit,Jean-Claude Cutz,Akira Sakurada,Ming‐Sound Tsao,Paul Hoskins,Jim Biagi,Prafull Ghatage,John Mazurka,Diane Provencher,Naomi Dore,Janet Dancey,Anthony Fyles |
| Citations | 143 |
| DOI | 10.1200/jco.2007.15.8808 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.15.8808?role=tab |
| OpenAlex ID | https://openalex.org/W2135939943 |
| PMID | 18591547 |
| Type | article |
| Year | 2008 |

## Paper authors

- [Laurie Elit](https://scholariq.org/researchers/laurie-elit/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Paper topics

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.